Higher mortality rate is associated with advanced age and periodic lateralized epileptiform discharges in patients with refractory status epilepticus

Arq Neuropsiquiatr. 2013 Mar;71(3):153-8. doi: 10.1590/s0004-282x2013000300005.

Abstract

Objective: To evaluate clinical data, electroencephalogram, etiology, classification, treatment, morbidity, and mortality in acute refractory status epilepticus.

Methods: Fifteen patients, mean age of 41.3 years-old, six males, with refractory status epilepticus, were retrospectively studied. All of them were followed by serial electroencephalogram or continuous electroencephalographic monitoring.

Results: The most common comorbidity was hypertension. Seven (46.7%) patients were diagnosed with previous symptomatic focal epilepsy. More than one etiology was identified in 40.0% of the cases. Status epilepticus partial complex was the most common (n=14, 93.3%), and discrete seizures were the most observed initial ictal pattern. Continuous intravenous midazolam was used in nine (60.0%) patients and continuous thiopental in three (20.0%). Nine (60.0%) participants died, one (6.6%) had neurological sequelae, and five (33.3%) presented no neurological sequelae.

Conclusions: Higher mortality rate was associated with advanced age and periodic lateralized epileptiform discharges. Midazolam proved to be a safe drug. The refractory status epilepticus is related to high mortality.

MeSH terms

  • Adult
  • Age Factors
  • Aged
  • Aged, 80 and over
  • Anticonvulsants / therapeutic use
  • Child
  • Child, Preschool
  • Electroencephalography
  • Female
  • Humans
  • Infant
  • Male
  • Midazolam / therapeutic use
  • Middle Aged
  • Prognosis
  • Retrospective Studies
  • Risk Factors
  • Seizures / physiopathology
  • Sex Factors
  • Status Epilepticus / drug therapy
  • Status Epilepticus / mortality*
  • Status Epilepticus / physiopathology
  • Treatment Outcome
  • Young Adult

Substances

  • Anticonvulsants
  • Midazolam